CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 153 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,256,645 | +786.9% | 84,282 | +418.7% | 0.03% | +900.0% |
| Q1 2023 | $141,691 | +25.1% | 16,249 | -10.1% | 0.00% | 0.0% |
| Q4 2022 | $113,305 | +163.5% | 18,071 | +24.8% | 0.00% | +200.0% |
| Q2 2022 | $43,000 | -92.3% | 14,479 | -90.9% | 0.00% | -97.4% |
| Q2 2020 | $557,000 | +75.7% | 159,465 | -25.6% | 0.04% | +46.2% |
| Q1 2020 | $317,000 | +131.4% | 214,436 | +700.4% | 0.03% | +100.0% |
| Q3 2019 | $137,000 | -66.1% | 26,790 | -46.5% | 0.01% | -80.6% |
| Q3 2017 | $404,000 | +861.9% | 50,077 | +128.7% | 0.07% | +235.0% |
| Q3 2015 | $42,000 | – | 21,897 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |